|
|
Article: RECEPTAGEN INITIATES CLINICAL DEVELOPMENT OF GROWTH BLOCKERS-DRUG CANDIDATE DEMONSTRATES "PROGRAMMED CELL DEATH" IN CANCER CELLS.
- Article from:
- Business Wire
- Article date:
- February 15, 1995
CopyrightCOPYRIGHT 1995 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEATTLE, WASH--(BUSINESS WIRE)--FEBRUARY 15, 1995--RECEPTAGEN LTD.(TSE: RCG ) Receptagen Ltd. today announced it has begun formal clinical development of its first "growth blocker" drug, as a result of recent company research demonstrating selective induction of programmed cell death, or "apoptosis", in cancer cells.
Receptagen is developing growth blocker drugs, a new class of minimally toxic biopharmaceuticals for the treatment of cancer and other life-threatening diseases marked by uncontrolled cell proliferation. With recent efficacy shown in cells, it has initiated development of the first generation of growth blockers that potentially lack the toxicities and ...